CDH2 and Familial prostate cancer: On the other hand, the elevation of N-cadherin has been shown to be a significant predictor of prostate cancer recurrence following radical prostatectomy, making it one of the few biomarkers capable of providing information for prostate cancer treatment follow-up [40, 49].